Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Vincristine 2Temozolomide 2Irinotecan 2Doxorubicin 2Cyclophosphamide 2Bone Marrow Transplantation 2robatumumab 1pegfilgrastim 1palbociclib 1lexatumumab 1ganitumab 1disaccharide tripeptide 1delta 24-sterol reductase 1copanlisib 1bempegaldesleukin 1Thiotepa 1Radiosurgery 1Plicamycin 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Interferon-gamma 1Immunotherapy, Adoptive 1INCB059872 1IL32 protein, human 1Granulocyte Colony-Stimulating Factor 1Genistein 1Filgrastim 1FANG vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma, Ewing × robatumumab × Clear all
NCT00617890 2018-08-23

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Merck Sharp & Dohme LLC

Phase 2 Terminated
219 enrolled 13 charts
Sarcoma

Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡